Tandem Meeting | Conference

Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Alina Markova, MD, on Topical Ruxolitinib Mechanism of Action in Cutaneous Chronic GVHD
May 19, 2022

Alina Markova, MD, speaks to the mechanism of action of topical ruxolitinib INCB018424 phosphate 1.5% cream vs oral ruxolitinib and other topical therapies used in the treatment of non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Uday R. Popat, MD, Reviews Post-Transplant Cyclophosphamide Vs Tacrolimus and Methotrexate to Prevent GVHD in AML/MDS
May 18, 2022

Uday R. Popat, MD, spoke about how well post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease was performed in this trial.

Alina Markova, MD, on the Rationale for Assessing Topical Ruxolitinib in Cutaneous Chronic GVHD
May 13, 2022

Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Uday R. Popat, MD, Discusses Rationale for Post-Transplant Cyclophosphamide as GVHD Prophylaxis in AML/MDS
May 11, 2022

Uday R. Popat, MD, spoke about the decision to use post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease.

Alina Markova, MD, on Key Findings With Topical Ruxolitinib in Cutaneous Chronic GVHD
May 10, 2022

Alina Markova, MD, highlights important findings from a study assessing topical ruxolitinib INCB018424 phosphate 1.5% cream as a treatment for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Nina Shah, MD, Shares Key Takeaways From Phase 2 KarMMa Trial Sub-Analysis of Ide-Cel in R/R Multiple Myeloma
May 06, 2022

Nina Shah, MD, spoke about her key takeaways from a sub-analysis of the phase 2 KarMMa trial assessing correlates of complete response among those treated with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Nina Shah, MD, Reviews the Rationale for Phase 2 KarMMa Trial Sub-Analysis of Ide-Cel CR Correlates in R/R Multiple Myeloma
May 04, 2022

Nina Shah, MD, spoke about analyzing correlates of complete response in patients with relapsed/refractory multiple myeloma who were treated with idecabtagene vicleucel.

Targeting CD117 With JSP191, TBI, and Fludarabine Appears Safe and Efficacious in MDS/AML
April 29, 2022

JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.

Study of Response to SARS-CoV-2 Vaccine Reveals Heterogeneous Outcomes in cGVHD
April 27, 2022

Patients with chronic graft-vs-host disease who were administered full series of the SARS-CoV-2 vaccine displayed varied immune responses, regardless of baseline characteristics.

Total Body Irradiation Plus Prophylactic PTCy, Tac, and MMF Yields Low cGVHD Incidence in Hematologic Cancer
April 27, 2022

Patients with hematologic cancer experienced a low incidence of chronic graft-versus-host disease after receiving a regimen consisting of myeloablative hematopoietic cell transplantation and total body irradiation plus prophylactic post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil.